55463-68-8

Usage

Class

Carbolines

Structure

Pentacyclic

Amino group position

2

Biological activities

Potential neuroprotective and antiproliferative agent

Potential applications

Drug target for treatment of various diseases

Upstream product

• 20798-52-1 2-bromo-6-(2-cyclohexylidenehydrazinyl)pyridine 
• 20798-17-8 2-bromo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indole 
• 26944-71-8 (6-bromopyridin-2-yl)hydrazine 
• 626-05-1 2,6-Dibromopyridine 

Relevant academic research and scientific papers

Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like prote

Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like prote

Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.